20/20 Biolabs, Inc. — Form 8-K

20/20 Biolabs (NASDAQ: AIDX) held an investor webinar on July 1, 2026, presenting its OneTest multi-cancer early detection (MCED) blood test strategy. The presentation highlights the February 3, 2026 Congressional passage of the Multi-Cancer Early Detection Screening Coverage Act, which establishes a statutory pathway for Medicare reimbursement of FDA-approved MCED tests beginning in 2028, covering ~67 million Medicare beneficiaries. OneTest uses 12 protein biomarkers with serial testing and machine learning, targeting FDA De Novo or PMA authorization; the company projects revenues reaching ~$100M over five years post-Medicare coverage with a 5% royalty pool to be shared with 'data investors,' and plans to acquire vertically integrated companies with $2–8M annualized revenues.